Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.45 | 2.65 | 3.37 | 6.11 | 7.50 | 2.13 | 1.94 | — |
Net Debt/EBITDA |
0.78 | 0.47 | 0.59 | 0.96 | 1.95 | (0.47) | (3.21) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 180.53% | 802.09% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.00) | (1.02) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.05 | 0.84 | 0.62 | 0.87 | 0.22 | 0.28 | 0.35 | — |
Capex/Depreciation |
0.04 | (0.01) | (0.58) | (0.73) | (0.06) | (0.01) | 0.00 | — |
Interest Coverage |
(3,676.85) | (2,158.64) | (1,878.67) | (1,555.39) | (32.02) | (9.94) | (2.51) | — |
| (88.60%) | (157.19%) | (79.69%) | (46.76%) | 192.16% | 19.07% | 13.84% | — | |
| (59.75%) | (103.89%) | (60.26%) | (39.06%) | (49.05%) | (165.63%) | (234.94%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(68.76%) | (182.70%) | (105.96%) | (53.38%) | (31.69%) | (312.04%) | (232.04%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.34) | (0.72) | (0.54) | (0.79) | (0.70) | (6.78) | (0.14) | — |
Cash per Share |
0.51 | 0.63 | 1.00 | 1.76 | 10.54 | 10.21 | 0.13 | — |
Shareholders Equity per Share |
0.47 | 0.47 | 0.82 | 1.70 | 9.88 | (25.22) | (2.66) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.47 | 0.47 | 0.82 | 1.70 | 9.88 | (25.22) | (2.66) | — |
Free Cash Flow |
(24.58) | (28.48) | (16.16) | (18.70) | (3.66) | (3.44) | (3.10) | — |
Working Capital |
34.07 | 18.41 | 24.05 | 39.85 | 51.13 | 3.66 | 3.48 | — |
Capital Expenditures |
0.01 | 0.00 | (0.15) | (0.17) | (0.03) | (0.01) | (0.14) | — |
Net Current Asset Value |
33.87 | 18.07 | 23.53 | 37.47 | 51.13 | (13.02) | (58.72) | — |
| Other line items | ||||||||
Quick Ratio |
3.37 | 2.49 | 3.07 | 5.80 | 7.25 | 1.95 | 1.90 | — |
Depreciation/Fixed assets |
2.45 | 1.47 | 0.89 | 1.01 | 3.28 | 4.43 | 0.27 | — |
Cash ROIC |
(34.49%) | (65.08%) | (29.72%) | (22.86%) | (3.45%) | (65.87%) | (72.11%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,621.05 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.34) | (0.72) | (0.53) | (0.78) | (0.70) | (6.76) | (0.14) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.02) | 0.00 | — |
Average Receivables |
6.30 | 1.98 | 2.48 | 2.97 | 1.71 | 2.64 | 2.64 | — |
Average Payables |
1.55 | 2.84 | 3.46 | 3.69 | 3.09 | 2.18 | 2.18 | — |
Average Assets |
39.31 | 32.70 | 42.79 | 54.78 | 33.13 | 7.29 | 3.73 | — |
Average Common Equity |
26.51 | 21.61 | 32.36 | 45.76 | (8.46) | (63.30) | (63.30) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates